ASCO GU 2018: Incidence and mortality of Renal Cell Carcinoma in the U.S.: A SEER-based Study Investigating Trends Over the Last Four Decades
San Francisco, CA (UroToday.com) Renal cell carcinoma (RCC) is the third most common urologic malignancy worldwide – due to increasing cross-sectional imaging, there have been prior studies demonstrating increasing incidence of RCC, particularly localized RCC. While there are many histologic subtypes, the majority of RCC’s present with clear cell subtype.
ASCO GU 2018: Trends and Morbidity for Minimally Invasive Versus Open Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma
San Francisco, CA (UroToday.com) Cytoreductive nephrectomy (CN) prior to systemic therapy for metastatic renal cell carcinoma (RCC) is recommended in patients with a surgically resectable primary tumor. Traditionally performed as open surgery, the advent of laparoscopic and robotic surgery provides a minimally invasive alternative to CN with a potential for accelerated recovery and earlier initiation of systemic therapy. The authors sought to compare the trends and morbidity of laparoscopic, robotic, and open CN for patients with metastatic RCC.
ASCO GU 2018: Renal Cell Carcinoma Primary Tumor Shrinkage on Vascular Endothelial Growth Factor Targeted Therapy - A Pooled Analysis
San Francisco, CA (UroToday.com) Cytoreductive nephrectomy (CRN) is an important treatment modality in patients with advanced renal cell carcinoma (RCC), however the role and timing in the context of vascular endothelial growth factor (VEGF) - targeted therapy (TT) remains under investigation. The aim of this study was to determine the efficacy of VEGF-TT to induce primary tumor shrinkage in advanced RCC.
ASCO GU 2018: Association of Age and Sex with Mortality Following Adjuvant Therapy for Renal Cell Cancer: Subgroup Analysis of the ASSURE (E2805) Trial
San Francisco, CA (UroToday.com) The benefit of vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) as adjuvant therapy after surgical treatment of renal cell carcinoma (RCC) tumors remains a subject of controversy. Given the uncertain risk-benefit ratio, identifying subgroups expected to derive benefit or harm from therapy could lead to a more precise approach to therapy. Because of known sex-differences in the pharmacokinetics and tissue distribution of VEGF-TKIs, the authors assessed the interaction of age and sex on treatment outcomes among patients in the phase III ASSURE trial (Adjuvant Sorafenib or Sunitinib for Unfavorable RCC).1
ASCO GU 2018:Oncologic and Functional Follow-up After Renal Mass Treatment
San Francisco, CA (UroToday.com) Dr. Campbell presented oncologic and functional follow-up after treating renal masses. According to him 3 separate points need to be considered:
ASCO GU 2018: Prospective Evaluation of Geriatric Assessments as Predictors of Complications and Functional Outcome After Major Urologic Tumor Surgery in the Older Population
San Francisco, CA (UroToday.com) Urologic surgery, particularly cystectomy, can be a long, difficult operation for patients, in terms of physical impact and post-operative recovery. As many of these disease processes affect the older population, patients undergoing major urologic surgery are uniformly older than other surgical specialties.
ASCO GU 2018: Interpreting Data on Renal Function Preservation After Nephrectomy: Has the EORTC Trial Put the Issue to Rest?
San Francisco, CA (UroToday.com) Dr. Parikh presented renal function preservation after nephrectomy and included the following 4 goals for renal cell carcinoma (RCC) surgery: